Gu, Y., Qiu, T., Mingjie, L., Dong, Y. (2025). Fruquintinib in combination with camrelizumab and paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.4042